ACADIA PHARMACEUTICALS INC - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Acadia Pharmaceuticals Inc. on May 29, 2025. The filing details the election of directors and the ratification of key corporate governance matters.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a current report focused solely on corporate governance events.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders and approved:
- Election of Class III Directors: Three nominees were elected to serve until the 2028 Annual Meeting.
- Catherine Owen Adams: 142,149,434 votes For; 2,923,385 votes Withheld.
- Laura A. Brege: 129,105,717 votes For; 15,967,102 votes Withheld.
- Elizabeth A. Garofalo, M.D.: 140,048,500 votes For; 5,024,319 votes Withheld.
- Advisory Vote on Executive Compensation: Approved with 142,156,754 votes For, 2,807,251 votes Against, and 108,814 votes Abstain.
- Ratification of Independent Auditor: Ernst & Young LLP was ratified for the fiscal year ending December 31, 2025, with 154,454,616 votes For, 926,490 votes Against, and 35,019 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors (Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo) through the 2028 Annual Meeting.
- Confirm the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025.
- Note the significant number of broker non-votes (10,343,307) recorded for the director elections and executive compensation vote.
- Review the definitive proxy statement filed on April 25, 2025, for detailed executive compensation disclosures referenced in the advisory vote.